JP2008528621A - 腎細胞ガンを処置するための方法 - Google Patents

腎細胞ガンを処置するための方法 Download PDF

Info

Publication number
JP2008528621A
JP2008528621A JP2007553304A JP2007553304A JP2008528621A JP 2008528621 A JP2008528621 A JP 2008528621A JP 2007553304 A JP2007553304 A JP 2007553304A JP 2007553304 A JP2007553304 A JP 2007553304A JP 2008528621 A JP2008528621 A JP 2008528621A
Authority
JP
Japan
Prior art keywords
des
weeks
administering
dose
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007553304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528621A5 (cg-RX-API-DMAC10.html
Inventor
ローレンス エリアス,
ゲイリー ウィザレル,
Original Assignee
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド filed Critical ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド
Publication of JP2008528621A publication Critical patent/JP2008528621A/ja
Publication of JP2008528621A5 publication Critical patent/JP2008528621A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2007553304A 2005-01-27 2006-01-27 腎細胞ガンを処置するための方法 Pending JP2008528621A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64749605P 2005-01-27 2005-01-27
PCT/US2006/003116 WO2006081510A2 (en) 2005-01-27 2006-01-27 Methods for treating renal cell carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011266809A Division JP2012046552A (ja) 2005-01-27 2011-12-06 腎細胞ガンを処置するための方法

Publications (2)

Publication Number Publication Date
JP2008528621A true JP2008528621A (ja) 2008-07-31
JP2008528621A5 JP2008528621A5 (cg-RX-API-DMAC10.html) 2009-01-29

Family

ID=36741121

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007553304A Pending JP2008528621A (ja) 2005-01-27 2006-01-27 腎細胞ガンを処置するための方法
JP2011266809A Pending JP2012046552A (ja) 2005-01-27 2011-12-06 腎細胞ガンを処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011266809A Pending JP2012046552A (ja) 2005-01-27 2011-12-06 腎細胞ガンを処置するための方法

Country Status (13)

Country Link
US (2) US20070014765A1 (cg-RX-API-DMAC10.html)
EP (1) EP1846020B1 (cg-RX-API-DMAC10.html)
JP (2) JP2008528621A (cg-RX-API-DMAC10.html)
KR (1) KR20070102576A (cg-RX-API-DMAC10.html)
CN (1) CN101132809A (cg-RX-API-DMAC10.html)
AU (1) AU2006207987B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0606774A2 (cg-RX-API-DMAC10.html)
CA (1) CA2595959A1 (cg-RX-API-DMAC10.html)
ES (1) ES2432141T3 (cg-RX-API-DMAC10.html)
IL (1) IL184865A (cg-RX-API-DMAC10.html)
MX (1) MX2007009012A (cg-RX-API-DMAC10.html)
RU (1) RU2404795C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006081510A2 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018514558A (ja) * 2015-04-27 2018-06-07 スサヴィオン バイオサイエンシーズ インコーポレイテッド がんおよび持続性ウイルス感染を処置するための組成物および方法
JP2019014743A (ja) * 2011-03-11 2019-01-31 アシスタンス ピュブリク−オピトー ドゥ パリAssistance Publique − Hopitaux De Paris 自己免疫関連障害または炎症性障害の治療のための低用量il−2の使用
JP2023029565A (ja) * 2011-03-11 2023-03-03 アシスタンス ピュブリク-オピトー ドゥ パリ 自己免疫関連障害または炎症性障害の治療のための低用量il-2の使用
JP2023546010A (ja) * 2020-10-09 2023-11-01 シンソークス, インコーポレイテッド Il-2コンジュゲートを用いた免疫腫瘍療法

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370399A4 (en) * 2008-12-11 2013-05-22 Agency Science Tech & Res GLUCOSE-PEG CONJUGATES TO REDUCE GLUCOSE TRANSPORT INTO A CELL
US20150299255A1 (en) * 2010-11-01 2015-10-22 Susavion Biosciences, Inc. Compositions and methods for modulating innate and adaptive immune systems
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
EP3129493B1 (en) 2014-04-09 2021-07-07 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CA3148135A1 (en) 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
WO2021050554A1 (en) 2019-09-10 2021-03-18 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
MX2022008770A (es) 2020-01-14 2022-10-07 Synthekine Inc Muteinas de la il2.
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002526A1 (en) * 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4931543A (en) 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
CN101028523A (zh) * 1995-11-30 2007-09-05 德克萨斯州立大学董事会 诊断和治疗肿瘤的方法及组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002526A1 (en) * 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019014743A (ja) * 2011-03-11 2019-01-31 アシスタンス ピュブリク−オピトー ドゥ パリAssistance Publique − Hopitaux De Paris 自己免疫関連障害または炎症性障害の治療のための低用量il−2の使用
JP2021006591A (ja) * 2011-03-11 2021-01-21 アシスタンス ピュブリク−オピトー ドゥ パリAssistance Publique − Hopitaux De Paris 自己免疫関連障害または炎症性障害の治療のための低用量il−2の使用
JP2023029565A (ja) * 2011-03-11 2023-03-03 アシスタンス ピュブリク-オピトー ドゥ パリ 自己免疫関連障害または炎症性障害の治療のための低用量il-2の使用
JP7561893B2 (ja) 2011-03-11 2024-10-04 アシスタンス ピュブリク-オピトー ドゥ パリ 自己免疫関連障害または炎症性障害の治療のための低用量il-2の使用
JP2018514558A (ja) * 2015-04-27 2018-06-07 スサヴィオン バイオサイエンシーズ インコーポレイテッド がんおよび持続性ウイルス感染を処置するための組成物および方法
JP2023546010A (ja) * 2020-10-09 2023-11-01 シンソークス, インコーポレイテッド Il-2コンジュゲートを用いた免疫腫瘍療法

Also Published As

Publication number Publication date
BRPI0606774A2 (pt) 2009-07-14
IL184865A0 (en) 2007-12-03
IL184865A (en) 2011-04-28
EP1846020B1 (en) 2013-08-21
AU2006207987B2 (en) 2011-09-15
AU2006207987A1 (en) 2006-08-03
JP2012046552A (ja) 2012-03-08
MX2007009012A (es) 2007-09-14
CA2595959A1 (en) 2006-08-03
US20100316595A1 (en) 2010-12-16
RU2404795C2 (ru) 2010-11-27
RU2007132125A (ru) 2009-03-10
KR20070102576A (ko) 2007-10-18
US8012465B2 (en) 2011-09-06
WO2006081510A3 (en) 2007-01-18
US20070014765A1 (en) 2007-01-18
CN101132809A (zh) 2008-02-27
ES2432141T3 (es) 2013-11-29
WO2006081510A2 (en) 2006-08-03
EP1846020A2 (en) 2007-10-24

Similar Documents

Publication Publication Date Title
JP2012046552A (ja) 腎細胞ガンを処置するための方法
JP6718494B2 (ja) 癌を処置するためのペグ化il−10の使用
EP3341012B1 (en) Methods of using interleukin-10 for treating diseases and disorders
AU2014208224A1 (en) New Stable Formulations of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor Fusion Protein
HK1172248A (en) Use of pegylated il-10 to treat cancer
HK1127553B (en) Use of pegylated il-10 to treat cancer
HK1201182B (en) Pegylated il-10 for use in treating lymphoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120816